EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Choosing the first biologic in pediatric Crohn's disease: Evidence, uncertainty, and the continuing role of anti-TNF therapy

Toshihiko Kakiuchi

Best Practice & Research Clinical Gastroenterology · 2026-10 · 102163

DOI: 10.1016/j.bpg.2026.102163 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Best Practice & Research Clinical Gastroenterology, 2026-10. Verfasst von Toshihiko Kakiuchi. Die Arbeit nennt 26 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Zitieren

APA

Kakiuchi, T. (2026). Choosing the first biologic in pediatric Crohn's disease: Evidence, uncertainty, and the continuing role of anti-TNF therapy. Best Practice & Research Clinical Gastroenterology, 102163. https://doi.org/10.1016/j.bpg.2026.102163

Vancouver

Kakiuchi T. Choosing the first biologic in pediatric Crohn's disease: Evidence, uncertainty, and the continuing role of anti-TNF therapy. Best Practice & Research Clinical Gastroenterology. 2026:102163. doi:10.1016/j.bpg.2026.102163

BibTeX
@article{Kakiuchi2026,
  author = {Kakiuchi, Toshihiko},
  title = {Choosing the first biologic in pediatric Crohn's disease: Evidence, uncertainty, and the continuing role of anti-TNF therapy},
  journal = {Best Practice & Research Clinical Gastroenterology},
  year = {2026},
  pages = {102163},
  doi = {10.1016/j.bpg.2026.102163}
}
Kostenlos starten →